Clinical Trials on Epidemic Meningitis in South Africa

Total 53 results

Novartis Pharmaceuticals

Terminated

Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS

Cryptococcal Meningitis

South Africa
University of Minnesota
National Institute of Allergy and Infectious Diseases (NIAID); Makerere University and other collaborators

Completed

Cryptococcal Optimal ART Timing Trial (COAT)

HIV Infections | AIDS | Cryptococcal Meningitis

Uganda, South Africa
University of Stellenbosch

Recruiting

Evaluation of New Biomarker-based Approaches for Improving the Diagnosis of Childhood Tuberculous Meningitis (TBMBIOMARKER)

Tuberculous Meningitis

South Africa
University of Witwatersrand, South Africa

Unknown

Persistence of Immunogenicity Following Reduced PCV Dosing Schedules in South African Children (PCV1+1_FU)

Pneumonia | Meningitis

South Africa
University of Witwatersrand, South Africa
University College, London

Completed

Reduced PCV Dosing Schedules in South African Infants (PCV1+1)

Pneumonia | Meningitis

South Africa
University of Cape Town

Completed

Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM (LASER-TBM)

HIV-1-infection | Tuberculosis Meningitis

South Africa
University of Cape Town
University of Cape Town Lung Institute; Leiden University Medical Center; European... and other collaborators

Recruiting

Same Day Diagnosis of Extrapulmonary TB (TB Serositis and TB Meningitis). (Epi-TB)

Tuberculosis, Extrapulmonary

South Africa, Zambia, Zimbabwe
National Institute of Allergy and Infectious Diseases...

Completed

High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals

HIV Infections | Cryptococcal Meningitis

Kenya, Thailand, Uganda, United States, Peru, South Africa, Zimbabwe, India
ANRS, Emerging Infectious Diseases
European and Developing Countries Clinical Trials Partnership (EDCTP); European...

Recruiting

Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis (INTENSE-TBM)

Tuberculous Meningitis

Côte D'Ivoire, Madagascar, South Africa, Uganda
Pfizer

Completed

Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults

Meningitis, Meningococcal

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis

Tuberculous Meningitis

South Africa, Zimbabwe, India, Kenya, Malawi, Mexico, Peru, Brazil, Philippines, Tanzania, Thailand, Vietnam
GlaxoSmithKline

Completed

A Sourcing Study to Collect Human Blood Samples From Healthy Adults

Meningitis, Meningococcal

Australia, Germany
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults

Meningitis, Meningococcal

Australia
Sanofi Pasteur, a Sanofi Company

Completed

Dose Comparison Study of Menactra® in US Children

Meningitis | Meningococcal Infection | Neisseria Meningitidis

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older

Meningitis | Meningococcal Infections | Meningococcal Meningitis | Invasive Meningococcal Disease

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis

HIV Infections | Meningitis, Cryptococcal

United States
GlaxoSmithKline

Completed

A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age

Meningitis, Meningococcal

Spain, Finland, Estonia, South Africa, Brazil, Mexico, Russian Federation, France, Turkey
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years

Meningococcal Disease | Meningococcal Meningitis

Australia, Canada
Pfizer

Completed

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Meningitis, Meningococcal

United States, Australia, Spain, Chile, Finland, Denmark, Estonia, Czech Republic, Germany, Lithuania, Poland, Sweden
Sanofi Pasteur, a Sanofi Company

Completed

Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States
University of Adelaide

Completed

Study to Assess Oropharyngeal Carriage of N. Meningitidis in South Australian School Leavers (B Part Of It)

Neisseria Meningitidis

Australia
University of Adelaide

Completed

The Long-term Impact of Invasive Meningococcal Disease in Australian Adolescents and Young Adults (AMEND)

Meningococcal Infections | Neisseria Infection | Neisseria Meningitis Sepsis

Australia
Novartis Vaccines
GlaxoSmithKline

Completed

Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine

Meningococcal Meningitis

United States
Novartis Vaccines

Completed

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents

Pertussis | Tetanus | Human Papillomavirus Infection | Meningococcal Meningitis

Costa Rica
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Novartis Vaccines

Completed

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults

Meningococcal Infections | Meningococcal Meningitis

United States
Pfizer

Completed

A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents

Meningitis, Meningococcal

Poland, Spain, Australia
National Institute of Allergy and Infectious Diseases...
Schering-Plough

Completed

SCH 39304 as Therapy for Acute Cryptococcal Meningitis in HIV-Infected Patients Followed by Maintenance Therapy

HIV Infections | Meningitis, Cryptococcal

United States
GlaxoSmithKline

Active, not recruiting

Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents

Meningitis, Meningococcal

Germany, United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

Meningitis, Meningococcal

United States, Australia, Argentina, Canada
Novartis Vaccines

Completed

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants

Meningitis, Meningococcal

United States, Argentina, Colombia
GlaxoSmithKline

Completed

Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.

Neisseria Meningitidis | Haemophilus Influenzae Type b

Australia
Sanofi Pasteur, a Sanofi Company

Completed

Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers

Measles | Rubella | Mumps | Varicella | Meningococcal Meningitis

United States, Chile
Pfizer
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDS

HIV Infections | Meningitis, Cryptococcal

United States
GlaxoSmithKline

Completed

Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines

Neisseria Meningitidis | Haemophilus Influenzae Type b

Australia
Sanofi

Completed

Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®

Pertussis | Tetanus | Diphtheria | Poliomyelitis | Meningococcal Meningitis

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers

Measles | Rubella | Mumps | Varicella | Meningococcal Meningitis

United States, Puerto Rico
GlaxoSmithKline

Completed

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States, Mexico
Pfizer

Terminated

Colombia Epidemiologic Surveillance Study (LEAP II)

Pneumonia | Sepsis | Bacteremia | Meningitis

Colombia, Brazil, Costa Rica
GlaxoSmithKline

Completed

Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States
Spartanburg Regional Healthcare System
Edward Via Virginia College of Osteopathic Medicine

Completed

The Effectiveness and Safety of Human Lumbar Puncture Assist Device (LPat) (LPat)

Encephalitis | Meningitis | Subarachnoid Hemorrhage | Intracranial Neoplasm | Guillain-Barré | Intracranial CNS Disorder

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers

Meningitis | Meningococcal Infection

United States
Novartis
Novartis Vaccines

Completed

Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

Meningitis | Meningococcal Infection

United States, China, Costa Rica, Guatemala, Panama, Peru
Inflammatix

Recruiting

HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis (SEPSIS-SHIELD)

Respiratory Tract Infections | Sepsis | Urinary Tract Infections | Intra-Abdominal Infections | Skin and Soft Tissue Infection | Suspected Meningitis/Encephalitis or Any Other Infection

United States, Greece
GlaxoSmithKline

Completed

Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b

Australia
Sanofi Pasteur, a Sanofi Company

Completed

Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines

Meningitis | Meningococcal Disease

Philippines
GlaxoSmithKline

Completed

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States, Mexico

Clinical Trials on Epidemic Meningitis in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations